23results about How to "Prolong life" patented technology

The utility model discloses a breathing machine humidifying tank and a breathing machine system, and relates to the field of medical instruments. The breathing machine humidifying tank comprises a tank body, a guide sleeve, a telescopic water bag and an operating rod. The tank main body is provided with a highest water line; the telescopic water bag is located in the tank body and horizontally arranged, the top of the telescopic water bag is higher than the highest water line, the telescopic water bag comprises a telescopic sleeve and a hard end plate, one end of the telescopic sleeve is connected with the tank body, the hard end plate is connected with the other end of the telescopic sleeve, and a water suction and drainage hole is formed in the hard end plate and lower than the highest water line. The guide sleeve and the telescopic water bag are arranged in the same direction, and the guide sleeve is connected with the tank body and corresponds to the telescopic water bag in position. And the operating rod penetrates through the guide sleeve, is matched with the guide sleeve and is sealed with the guide sleeve, and the operating rod is connected with the hard end plate. The breathing machine humidifying tank is installed on the breathing machine main machine, and a temperature and humidity sensor and a push-pull structure are arranged in a matched mode to obtain the breathing machine system. According to the utility model, the temperature and humidity of the humidified air at the patient end can be optimal.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

Provided are a steel material and a method for producing the same. The steel material exhibits excellent hydrogen embrittlement resistance in a high-pressure hydrogen gas environment and is, therefore, suitable for use in hydrogen storage tanks, hydrogen line pipes, and the like. A steel material for a high-pressure hydrogen gas environment has a predetermined chemical composition. The steel material has a tensile strength of 560 MPa or higher, and a fracture toughness value KIH exhibited by the steel material in a high-pressure hydrogen gas atmosphere is 40 MPa ·m1 / 2 or higher.

The invention discloses an extracellular vesicle for inducing monocyte differentiation as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The invention particularly discloses application of extracellular vesicles separated from M1 type macrophages in preparation of monocyte-derived macrophages, preparation of products for preparing the monocyte-derived macrophages or preparation of medicines for treating tumors in non-disease diagnosis and treatment. The extracellular vesicles separated from the M1 type macrophages can induce monocytes to be differentiated into anti-tumor macrophages through a TNF-alpha mediated pathway, have excellent blood-brain barrier penetrating power, can effectively reduce the tumor volume and prolong the lifetime, and are used for treating tumors such as glioma, and off-target toxicity is not observed.

The present invention pertains to a negative electrode for a lithium secondary battery, a method for manufacturing same, and a lithium secondary battery including same. More specifically, the negative electrode for a lithium secondary battery according to the present invention has a protective layer containing a three-dimensional structure composed of metal and lithium nitride, and thus uniform ionic conductivity and electrical conductivity can be induced on the surface of the negative electrode.

The invention belongs to the technical field of medicine. More specifically, the invention relates to application of telbivudine in preparation of drugs for preventing or treating breast cancer. The invention provides an application of telbivudine in preparation of a medicine for preventing or treating breast cancer. The invention proves that the telbivudine has an anti-breast cancer effect for the first time, and the telbivudine as the NSD2 inhibitor can effectively inhibit the growth of the breast cancer. Meanwhile, the telbivudine can remodel the immunosuppressive tumor microenvironment, reduce the infiltration of regulatory T cells (Treg), and significantly enhance the effector function of CD8 + T cells. More importantly, the telbivudine and the PD-1 antibody are combined to show a remarkable synergistic effect in a breast cancer mouse model, and the tumor inhibition effect and survival benefit are superior to those of a single drug. The combination scheme of the telbivudine and the PD-1 antibody significantly improves the sensitivity of breast cancer to immunotherapy, provides a new scheme for solving the problem of low clinical response rate of breast cancer immunotherapy, and has good application prospects and application values.

The invention discloses an ad hoc network dynamic topology routing optimization method and system based on a Deepseek lightweight large model, and the method specifically comprises the steps: collecting the information of each node in an ad hoc network, and standardizing the node information into a feature vector format which can be analyzed by the Deepseek model; the standardized node feature vectors are input into a Deepseek model, and the topological structure change trend in a short time in the future is predicted; generating a routing path selection strategy based on a topology change trend predicted by the model, testing in an ad hoc network simulation platform, and adjusting feature weight distribution of the model according to a test result; and deploying the adjusted strategy to an actual network, collecting routing performance data in real time as a new sample input model, iteratively updating the model, and improving the accuracy of topology prediction and routing optimization. According to the method, a response can be quickly made to a new network topology, the convergence speed is increased, accurate routing selection can be realized, node energy consumption is reduced, and the life cycle of the ad hoc network is prolonged.

The application discloses an engineered potent dendritic cell vaccine and a preparation method and application thereof, and utilizes a nano-scale antigen delivery mode to fuse tumor antigens with cationic liposomes, destroys the stability of a lysosome membrane by means of cationic liposome charge interaction, makes part of the antigens escape into a cytoplasm to be cross-presented through an MHC I pathway, gives the DCs the ability to activate a cellular immune response to resist tumors, on the other hand, gives the DCs T cell directivity through a synthetic immunology method, promotes the interaction and signal transmission of DC-T cells, and the combination of the two mechanisms can overcome the low response rate problem of the existing DC vaccine, and maximizes the anti-tumor immune response.

The present invention relates to a coating composition which is an anticorrosive paint for ship structures and can be coated by a regular airless painting machine, and is solvent-free or contains a low solvent content. The coating composition according to an embodiment of the present invention may exhibit excellent pot life, atomization and drying time, and is eco-friendly due to having a high solid content and thus lower VOC emissions.

The invention relates to the technical field of fuel management, in particular to a reactor core loading method. According to the method, a reactor core is composed of 121 fuel assemblies, the Nth cycle of a unit is determined to be a first new cycle from an 18-month design cycle to a 24-month design cycle, the new fuel assemblies are divided into four areas for loading according to the number of gadolinium rods in the new fuel assemblies, and the number of the gadolinium rods in the new fuel assemblies in the four areas is 24, 20, 16 and 8 respectively; in the second new cycle, the new fuel assembly is divided into six areas for loading according to the number of the gadolinium rods in the new fuel assembly, and the number of the gadolinium rods in the new fuel assembly in the six areas is 32, 28, 24, 20, 16 and 8 respectively; the new fuel assembly is a fuel assembly with U-235 enrichment degree of 4.95%, and the position of the new fuel assembly in the reactor core meets one-eighth symmetry; and the loading numbers of the new fuel assemblies in the new cycle with the odd number and the new cycle with the even number are the same or different. The problem of insufficient economy in the prior art is solved by optimizing the enrichment degree of the fuel assembly and adjusting the batch refueling quantity and the arrangement of the reactor core.

The application relates to the field of medical technology, in particular to application of PTPRT as a biomarker and target point for predicting the curative effect of lung cancer immunological checkpoint treatment. The application provides application of the expression amount of PTPRT in curative effect prediction or evaluation of immunological checkpoint treatment of cancer. The experiment of the application shows that low expression of PTPRT can accurately predict the progression-free survival (PFS) of lung cancer patients after receiving immunological checkpoint treatment as a marker for predicting the curative effect of lung cancer immunological checkpoint treatment. Inhibition of PTPRT can increase the proportion of CD8+ T cells infiltrating tumors, and synergistically enhances the anti-tumor effect of an immunological checkpoint inhibitor.

The invention discloses a liver cancer screening system based on platelet alpha particle super-resolution imaging, which combines the proportion of alpha particle'regular distribution 'platelets and clinical indexes AFP and DCP to screen liver cancer, and can improve the sensitivity of early hepatocellular carcinoma screening. Besides, according to the cancer broad-spectrum screening system provided by the invention, the proportion of alpha-particle'regular distribution 'platelets or the proportion of alpha-particle'N < = 30' platelets is taken as a cancer broad-spectrum screening marker, and the higher the proportion of the alpha-particle'regular distribution 'platelets or the lower the proportion of alpha-particle'N < = 30' platelets is, the higher the proportion of alpha-particle'regular distribution 'platelets is or the lower the proportion of alpha-particle'N < = 30' platelets is. When the cancer risk is higher, cancer broad-spectrum screening is carried out, and high specificity and sensitivity are achieved.

The invention discloses application of a small molecule compound GK921 in preparation of a medicine for treating sepsis. The structural formula of the small molecule compound GK921 is shown as a formula (I). The key positive regulation effect of the Set protein in macrophage-mediated inflammatory response is disclosed for the first time, and the Set protein is determined as a novel target spot for treating inflammatory diseases such as sepsis. Based on the discovery, the small molecular compound GK921 targeting the Set protein is successfully identified through high-throughput screening. Experiments show that the GK921 efficiently inhibits the expression of key inflammatory factors in a cell model through a mechanism dependent on Set protein, and significantly prolongs the lifetime in a sepsis mouse model. The invention not only provides a brand-new candidate drug GK921 for treatment of sepsis, but also opens up a brand-new treatment approach and application field for known compounds through a strategy of'new use of old drugs', and has important theoretical innovation value and clinical transformation prospect.

The application belongs to the field of biological medicine, and discloses a pharmaceutical composition of water channel protein inhibitor combined with temozolomide for treating brain glioma, wherein the pharmaceutical composition comprises AQP4 inhibitor AER270 and TMZ. The application further discloses a pharmaceutical preparation comprising the above pharmaceutical composition and application of the pharmaceutical preparation in preparation of a medicine for treating brain glioma. The composition provided by the application provides an effective drug combination strategy for treating brain glioma, and it is found for the first time that AER270 and TMZ have a synergistic effect on the treatment of brain glioma.

The invention discloses an amplification culture medium, an amplification method and application of an iPSC (induced pluripotent stem cell) derived hematopoietic progenitor cell population, and relates to the technical field of cell culture. According to the amplification culture medium provided by the invention, animal-derived components are replaced by chemical small molecule combinations, so that the safety of cell products is remarkably improved; the yield of NK cells cultured by the culture medium is greatly increased, the HPC amplification multiple is increased to 2.5 times or more of that of a traditional process by adding tranexamic acid, and the bottleneck of industrial production is broken through. The method provided by the invention improves the process stability. The cells amplified according to the method provided by the invention strengthen the pertinence of lung cancer treatment.

This invention discloses the preparation and application of radiofrequency thermoresponsive platinum ion crosslinked black phosphorus nanogel. The nanogel has a core-shell structure, comprising a core composed of a radiofrequency thermosensitive agent and chemotherapeutic drugs, and a shell constructed from a thermosensitive nanopolymer. The thermosensitive nanogel BP-Pt@PNA prepared using the above components exhibits radiofrequency thermosensitive properties. Simultaneously, the introduction of the thermosensitive nanopolymer improves the stability of the radiofrequency thermosensitive agent and chemotherapeutic drugs, enabling long-term drug retention and fully leveraging the synergistic effect of non-invasive radiofrequency thermotherapy and chemotherapy. This drug-loaded nanogel can achieve multimodal treatment applications, including non-invasive radiofrequency thermotherapy-chemotherapy synergistic antitumor therapy and invasive radiofrequency ablation-chemotherapy-vascular embolization synergistic antitumor therapy, demonstrating significant clinical translational potential.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and temozolomide for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER270 and TMZ. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. The composition provided by the invention provides an effective drug combination strategy for treatment of brain glioma, and it is found for the first time that the combination of AER270 and TMZ has a synergistic effect on treatment of brain glioma.

This invention relates to the synergistic anticancer application of redox-responsive condensates (FFSSFF) for delivering jujube extract and 3-methyladenine. Specifically, this invention relates to the application of redox-responsive condensates in the preparation of targeted drug delivery products, wherein the targeted drug delivery products release drugs in response to glutathione. The active ingredients in the targeted drug delivery products are jujube extract and 3-methyladenine. This invention utilizes an FFSSFF carrier designed based on the LLPS principle, integrating redox-sensitive disulfide bond linkage modules to achieve spatiotemporally controlled drug delivery within a tumor tissue-specific microenvironment with high glutathione concentrations.

The invention provides application of honokiol in preparation of a medicine for treating mutated drug-resistant solid tumors and / or brain metastatic tumors of the drug-resistant solid tumors. Researches find that honokiol can generate an obvious inhibition effect on a mutant drug-resistant strain, and can simultaneously have an obvious inhibition effect on in-situ and brain metastases of the drug-resistant strain. Therefore, honokiol has an obvious treatment effect on the drug-resistant solid tumor and the brain metastasis tumor of the drug-resistant solid tumor, the lifetime of a patient is prolonged, and a new and effective treatment choice is provided for the drug-resistant solid tumor and the brain metastasis tumor of the drug-resistant solid tumor.

This invention relates to the field of biomedical technology, and particularly to a responsive RNA delivery system for glioma, its preparation method, and its applications. By fusing the blood-brain barrier-penetrating peptide ANG-2 to mediate cross-blood-brain barrier delivery, and simultaneously combining it with Siglec-15-mediated immune targeting recognition, a dual-targeting mechanism is constructed. This guides the delivery system to accurately identify glioma lesions, significantly increasing the enrichment of the delivery system in the lesion area, laying the foundation for the efficacy of nucleic acid drugs, effectively improving the targeting and effectiveness of treatment, and avoiding damage to normal brain tissue. The dual stimulation release mechanism of acid response and reactive oxygen species response can accurately respond to endogenous stimuli within glioma lesions and cells. Through the synergistic combination of the GO-C14 carrier and charge-reversed polylysine, the loading efficiency of YTHDF2 siRNA is effectively improved, while simultaneously enhancing the cyclic stability of nucleic acid drugs in vivo.

This invention belongs to the field of chemical pharmaceutical technology, specifically relating to a heterocyclic compound, its preparation method, application, and pharmaceutical composition for preventing and treating tumors. The heterocyclic compound provided by this invention exhibits significantly enhanced activity, selectively inhibiting RET activity, overcoming the drug resistance problem of existing RET inhibitors, possessing good pharmacokinetic properties, better solubility, reducing treatment costs for patients, and increasing patients' access to new drugs. This invention also provides the application of the heterocyclic compound described above or the heterocyclic compound prepared by the method described above in the preparation of RET inhibitors, tumor prevention drugs, or tumor treatment drugs. The compound provided by this invention can effectively inhibit the growth of various tumor cells, especially inhibiting RET kinase and selectively inhibiting RET lung cancer cells.

The present disclosure features compositions and methods useful for treating a condition for which deamination of adenosine in RNA results in a therapeutic outcome in a subject in need thereof.

The application discloses application of Hsap_1847317_1SS12GA_R+1 in preparation of a product for detecting tumor immunotherapy drug resistance, the immunotherapy is an immune checkpoint inhibitor treatment, and a nucleotide sequence of the Hsap_1847317_1SS12GA_R+1 is shown as SEQ ID NO. 1. In the technical scheme provided by the application, through a three-stage research process of screening-training-verification, it is found for the first time that Hsap_1847317_1SS12GA_R+1 is closely related to non-small cell lung cancer immunotherapy drug resistance, and it is confirmed that the Hsap_1847317_1SS12GA_R+1 can be used as an efficient detection marker. Research results show that in blood of patients after immunotherapy drug resistance, the expression amount of the Hsap_1847317_1SS12GA_R+1 is significantly up-regulated by about 10 times (P<0.0001), and excellent statistical significance is shown.